Dataset Information

Identification of a Novel Glycolysis-Related LncRNA Signature for Predicting Overall Survival in Patients With Bladder Cancer.

ABSTRACT:

Background

Both lncRNAs and glycolysis are considered to be key influencing factors in the progression of bladder cancer (BCa). Studies have shown that glycolysis-related lncRNAs are an important factor affecting the overall survival and prognosis of patients with bladder cancer. In this study, a prognostic model of BCa patients was constructed based on glycolysis-related lncRNAs to provide a point of reference for clinical diagnosis and treatment decisions.

Methods

The transcriptome, clinical data, and glycolysis-related pathway gene sets of BCa patients were obtained from The Cancer Genome Atlas (TCGA) database and the Gene Set Enrichment Analysis (GSEA) official website. Next, differentially expressed glycolysis-related lncRNAs were screened out, glycolysis-related lncRNAs with prognostic significance were identified through LASSO regression analysis, and a risk scoring model was constructed through multivariate Cox regression analysis. Then, based on the median of the risk scores, all BCa patients were divided into either a high-risk or low-risk group. Kaplan-Meier (KM) survival analysis and the receiver operating characteristic (ROC) curve were used to evaluate the predictive power of the model. A nomogram prognostic model was then constructed based on clinical indicators and risk scores. A calibration chart, clinical decision curve, and ROC curve analysis were used to evaluate the predictive performance of the model, and the risk score of the prognostic model was verified using the TCGA data set. Finally, Gene Set Enrichment Analysis (GSEA) was performed on glycolysis-related lncRNAs.

Results

A total of 59 differentially expressed glycolysis-related lncRNAs were obtained from 411 bladder tumor tissues and 19 pericarcinomatous tissues, and 9 of those glycolysis-related lncRNAs (AC099850.3, AL589843.1, MAFG-DT, AC011503.2, NR2F1-AS1, AC078778.1, ZNF667-AS1, MNX1-AS1, and AC105942.1) were found to have prognostic significance. A signature was then constructed for predicting survival in BCa based on those 9 glycolysis-related lncRNAs. ROC curve analysis and a nomogram verified the accuracy of the signature.

Conclusion

Through this study, a novel prognostic prediction model for BCa was established based on 9 glycolysis-related lncRNAs that could effectively distinguish high-risk and low-risk BCa patients, and also provide a new point of reference for clinicians to make individualized treatment and review plans for patients with different levels of risk.

SUBMITTER: Zheng Z

PROVIDER: S-EPMC8417422 | biostudies-literature |

REPOSITORIES: biostudies-literature

ACCESS DATA

Similar Datasets

Project description:BackgroundCuproptosis is a novel form of cell death referred to as copper-dependent cytotoxicity. The regulation of proptosis is becoming an increasingly popular cancer treatment modality. To date, few studies have attempted to identify the cuproptosis-related long non-coding RNAs (CRLs). In this study, we sought to investigate the CRLs and construct a novel prognostic model for colorectal cancer (CRC).MethodsThe RNA-sequencing data of CRC patients were obtained from The Cancer Genome Atlas database. An analysis was conducted to identify the differentially expressed long non-coding RNAs, and a correlation analysis was performed to identify the CRLs. A univariate Cox analysis was conducted to select the prognostic CRLs. Based on a least absolute shrinkage and selection operator regression analysis, a prognostic signature comprising the 22 identified CRLs was constructed. A survival receiver operating characteristic curve analysis was conducted to evaluate the performance of the signature. Finally, an in vitro analysis was performed to investigate the function of lncRNA AC090116.1 in the CRC cells.ResultsA signature comprising 22 CRLs was developed. The patients in the training and validation sets were divided into the low- and high-risk groups and had significantly different survival probabilities. This signature had outstanding prognostic accuracy in predicting the 5-year overall survival of patients [training set, area under the curve (AUC) =0.820; validation set, AUC =0.810]. The pathway enrichment analysis showed that the differential genes between low and high groups were enriched in several important oncogenic- and metastatic-associated processes and pathways. Finally, the in vitro experiments showed that AC090116.1 silencing promoted the cuproptosis processes and suppressed cell proliferation.ConclusionsOur findings provided promising insights into the CRLs involved in CRC. The signature based on CRLs has been successfully devised to prognosticate the clinical outcomes and treatment responses in patients.